The Nucleoside Analogue NITD008 , Alone or Combined With Ribavirin, Potently Reduces Hepatitis E Virus Infection in Humanised Mice
Liver International · 2026-12 · 46 (12)
DOI: 10.1111/liv.70955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 11.11.2026. Verfasst von Annika Volmari und 6 weiteren Autor:innen. Beteiligte Einrichtung: I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Ribavirin, Hepatitis E, Antiviral Agents, Hepatitis E virus. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Infektionsforschung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background and Aims Hepatitis E virus (HEV) infection is becoming increasingly clinically relevant worldwide, but no approved antiviral therapy currently exists. Ribavirin (RBV) is used off‐label for immunosuppressed patients with chronic hepatitis E, although it is effective in only 80% of patients and linked to side effects. The nucleoside analogue NITD008 was shown to be effective against a broad range of RNA viruses. We aimed to evaluate the efficacy of NITD008, alone or in combination with RBV, in humanised mice stably infected with HEV.
Methods
Mice received either NITD008 alone (20 mg/Kg/day) by oral gavage for up to 2 weeks, or 5 mg/Kg NITD008 alone or in combination with RBV (50 mg/Kg). Viral changes were determined in faeces, blood and intrahepatically.
Results
NITD008 efficiently reduced HEV loads to undetectable levels in serum and by > 4log 10 in faeces within 1 week. Intrahepatic analysis showed a ∆log 10 : 2.5 reduction in HEV RNA levels in treated mice compared to controls after 2 weeks. Imaging showed fewer HEV‐RNA‐positive human hepatocytes in treated mice. NITD008 did not increase serum markers of hepatocyte death. Combination therapy induced stronger suppression of HEV RNA in faeces (∆log 10 : 5.02) than RBV monotherapy (∆log 10 : 1.08), despite lower NITD008 doses.
Conclusions
This study demonstrates the non‐toxicity of NITD008 towards human hepatocytes and more potent antiviral activity compared to RBV in HEV‐infected mice. Combination regimens with RBV showed strong additive activity. The study suggests that HEV clearance may be achieved in immunosuppressed patients by using and further developing this class of direct antiviral drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- German Center for Infection Research (DZIF), Hamburg, Germany.
- Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Annika Volmari, Tassilo Volz, Junfei Chen, Lena Allweiss, Marc Lütgehetmann, Maura Dandri
Förderung
- Deutsches Zentrum für Infektionsforschung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Volmari, A., Hinte, F., Volz, T., Chen, J., Allweiss, L., Lütgehetmann, M., & Dandri, M. (2026). The Nucleoside Analogue NITD008 , Alone or Combined With Ribavirin, Potently Reduces Hepatitis E Virus Infection in Humanised Mice. Liver International, 46(12). https://doi.org/10.1111/liv.70955
Vancouver
Volmari A, Hinte F, Volz T, Chen J, Allweiss L, Lütgehetmann M, et al. The Nucleoside Analogue NITD008 , Alone or Combined With Ribavirin, Potently Reduces Hepatitis E Virus Infection in Humanised Mice. Liver International. 2026;46(12). doi:10.1111/liv.70955
BibTeX
@article{Volmari2026,
author = {Volmari, Annika and Hinte, Florian and Volz, Tassilo and Chen, Junfei and Allweiss, Lena and Lütgehetmann, Marc and Dandri, Maura},
title = {The Nucleoside Analogue NITD008 , Alone or Combined With Ribavirin, Potently Reduces Hepatitis E Virus Infection in Humanised Mice},
journal = {Liver International},
year = {2026},
volume = {46},
number = {12},
doi = {10.1111/liv.70955}
}
EUVIMED